$Karyopharm(KPTI)$ "The combination of selinexor and dexamethasone demonstrated limited efficacy and significant toxicity in patients with relapsed/refractory multiple myelom (RRMM)," concludes the FDA.
"Given the limited efficacy and significant toxicity demonstrated in this population, it is unclear whether treatment with selinexor-dexamethasone provides a clinically meaningful benefit that outweighs the risks of treatment. "